What question did this study set out to answer?

To evaluate long-term adherence to Elexacaftor/Tezacaftor/Ivacaftor (ETI) and Ivacaftor (IVA) in patients with cystic fibrosis.

March 14, 2026Open Access

Long-Term Adherence to Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis

To evaluate long-term adherence to Elexacaftor/Tezacaftor/Ivacaftor (ETI) and Ivacaftor (IVA) in patients with cystic fibrosis.
Analyzed pharmacy refill data over three years
Monitored adherence to ETI and IVA
Calculated adherence rates at multiple time points
High adherence to ETI and IVA observed initially
Adherence levels declined over the three-year period
Refill data indicated consistent patterns of medication usage

Three-year adherence to ETI and IVA based on pharmacy refill data was high, yet declined over time.

KI fragen

Bookmark

View Full Paper

Hansen et al. (Wed,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper